Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an announcement.
Neuren Pharmaceuticals has provided an updated notification of its ongoing on-market share buy-back program for its ordinary fully paid shares on the ASX, coded NEU. The update records that a total of 140,700 shares had been repurchased prior to the previous trading day, with an additional 16,000 shares bought back on that day.
The latest daily disclosure, dated 17 April 2026, follows an initial buy-back notification lodged in February and a prior update in March, underscoring that the program remains active. This steady execution of the buy-back may signal management’s confidence in the company’s valuation and serves to gradually reduce the number of shares on issue, potentially enhancing earnings per share for existing investors.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$19.10 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is an Australia-listed biotechnology company focused on developing pharmaceutical therapies, with its ordinary fully paid shares trading on the ASX under the code NEU. The company operates in the biopharmaceutical sector, where capital management actions such as on-market share buy-backs can influence shareholder value and market perception of its growth prospects.
Average Trading Volume: 546,037
Technical Sentiment Signal: Sell
Current Market Cap: A$1.58B
See more insights into NEU stock on TipRanks’ Stock Analysis page.